In this study, six mononuclear metal chelated complexes were designed and synthesized from a newly synthesized (E)-N′-((E)-1-(2-(p-tolyl)hydrazono)propan-2-ylidene)benzohydrazide Schiff base ligand. The chemical structures of the synthesized compounds were fully characterized using various techniques such as CHN analysis, infrared, proton nuclear magnetic resonance, mass spectral analysis, and conductivity measurements. The antioxidant activity of the metal complexes against active free radicals was determined through a 2,2-diphenyl-2-picryl-hydrazyl free radical scavenging experiment. Furthermore, all compounds were screened for antimicrobial, antifungal, and anticancer activities. Preliminary in vitro antibacterial and antifungal screening activities revealed that the complexes showed higher activity against the tested strains than those of the free ligand. The Mn(II) complex showed promising activity against HepG2 cells with very low IC50 (1.537 µg/ml). Molecular docking was used to predict the binding between the Schiff base ligand (L) and the different receptors. The docking study provided useful structural information for inhibition studies.